Company intelligence / Profile preview
Siam Bioscience Co., Ltd.
Pathum Wan, Bangkok, Thailandsiambioscience.com ↗
- Ownership
- Private
- Employees
- ~125
- Development stage
- Commercial
01
Overview
Siam Bioscience has successfully launched both their own pipeline products and partners' products via technology transfer. They began commercial operations in 2016, producing two biopharmaceuticals: one for treating anemia in patients with kidney failure, and another for reducing the risk of infection among cancer patients receiving chemotherapy.
- Therapeutic areas
- OncologyNephrology
- Modalities
- BiopharmaceuticalsCell and gene therapy (CGT)Advanced therapy medicinal products (ATMPs)OligonucleotidesBispecific monoclonal antibodiesAntibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
AstraZeneca (COVID-19 vaccine production)CIMAB S.A. (Cuba)Mahidol University
Beyond the preview
Go deeper on Siam Bioscience Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Siam Bioscience Co., Ltd..